David O. Calligaro

机构：Eli Lilly (United States)

发表论文 100 篇 · 总被引 4016 次 · h-index 34

代表论文

• Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor (2011 · Journal of Neuroscience · 被引 374)
• Adipsin, a Biomarker of Gastrointestinal Toxicity Mediated by a Functional γ-Secretase Inhibitor (2003 · Journal of Biological Chemistry · 被引 338)
• Preclinical pharmacological profile of the selective 5-HT 1F receptor agonist lasmiditan (2010 · Cephalalgia · 被引 214)
• The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans (2015 · Journal of Neuroscience · 被引 210)
• Olanzapine: a basic science update (1999 · The British Journal of Psychiatry · 被引 151)
• Muscarinic mechanisms of antipsychotic atypicality (2003 · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 被引 140)